product pipeline

KSD-101. The company's debut pipeline is an autologous DC vaccine for EBV-related diseases, which has completed dual reporting in China and the U.S., and is China's first original dendritic cell vaccine (DC vaccine) product to receive FDA IND approval.

Hematologic Tumors:

The safety and significant efficacy of KSD-101 have been validated in clinical IIT studies of single-agent treatment of relapsed and refractory hematologic tumors, and some of the initial research results have been presented at several congresses, such as the International Congress of EBV and KSHV 2024, the Annual Meeting of the European Hematology Association (EHA) 2024, ASH 2023, and other congresses, which have attracted international attention.

solid tumor

The clinical IIT study of KSD-101 monotherapy for recurrent metastatic nasopharyngeal carcinoma is progressing steadily at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology and Sun Yat-sen University Cancer Prevention and Control Center, with encouraging preliminary data.